Eton Pharmaceuticals shares have climbed about 108% over the past six months, far outpacing the industry's 0.7% growth, on strong commercial execution and an expanding rare-disease portfolio. Product sales reached $61.9 million in the first half of 2026, up from $32.9 million a year earlier, while second-quarter revenues jumped 99% year over year to $37.6 million, helped by the addition of Hemangeol. Eton has raised its 2026 revenue outlook twice this year, from an initial expectation of more than $110 million in March to more than $120 million in May and more than $145 million in August, and it expects an adjusted EBITDA margin of at least 35%. The company relaunched Hemangeol in May 2026 as the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy, transitioning roughly 95% of existing patients to its Eton Cares program by the end of June. Eton is also expanding its portfolio with the launch of Desmoda and Impavido, a planned Khindivi label expansion for children under five with adrenocortical insufficiency with a potential FDA approval in the first half of 2027, and the August acquisition of ASN-001, a late-stage candidate for moderate infantile hemangiomas that management believes could become its largest pipeline revenue opportunity.
Eton Pharmaceuticals IncEton raised 2026 revenue guidance twice to over $145 million with at least 35% adjusted EBITDA margin
Alnylam Pharmaceuticals Inc
Aldeyra The
Amarin Corporation PLC